StockData
Protara Therapeutics, Inc. logo

Protara Therapeutics, Inc. (TARA) stock

TARANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/30
$2.34+0.02 (+0.86%)

Close on Nov 18, 2026Market cap $138.28MP/E –Yield –

Protara Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

No pe ratio figures for Protara Therapeutics

Protara Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Protara Therapeutics figures

See a number that looks wrong?